Conditions

Colorectal Cancer Endometrial Cancer Head and Neck Cancer Liver Cancer Lung Cancer Melanoma (Skin)Pancreatic Cancer Testicular Germ Cell Tumor Unspecified Adult Solid Tumor, Protocol Specific

Keywords

stage IV colon cancerrecurrent non-small cell lung cancerstage II pancreatic cancerstage III pancreatic cancerrecurrent pancreatic cancerrecurrent colon cancerextensive stage small cell lung cancerrecurrent small cell lung canceradvanced adult primary liver cancerrecurrent adult primary liver cancerstage IV endometrial carcinomarecurrent endometrial carcinomastage III malignant testicular germ cell tumorrecurrent malignant testicular germ cell tumorstage IV papillary thyroid cancerstage IV follicular thyroid cancerthyroid gland medullary carcinomaanaplastic thyroid cancerrecurrent thyroid cancerstage IV melanomarecurrent melanomastage IV non-small cell lung cancerunspecified adult solid tumor, protocol specificuntreated metastatic squamous neck cancer with occult primary

Interventions

aldesleukinBiological

ras peptide cancer vaccineBiological

sargramostimBiological

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

DISEASE CHARACTERISTICS: * Histologically confirmed solid tumors potentially expressing mutant ras, including colon, lung, pancreas, thyroid, endometrial, head and neck, testicular, hepatocellular, and melanoma * Ras mutations must be one of the following point mutations at codon 12: * Glycine to cysteine * Glycine to aspartic acid * Glycine to valine * Metastatic disease for which no known chemotherapy or radiotherapy would increase survival * Tumor tissue must be available for determination of ras mutation * No prior CNS metastases PATIENT CHARACTERISTICS: Age: * 18 and over Performance status: * ECOG 0-1 Life expectancy: * More than 3 months Hematopoietic: * WBC at least 2,000/mm\^3 * Platelet count at least 100,000/mm\^3 Hepatic: * Bilirubin no greater than 2.0 mg/dL * SGOT/SGPT no greater than 4 times normal * No hepatitis B or C infection Renal: * Creatinine no greater than 2.0 mg/dL Cardiovascular: * No active ischemic heart disease (New York Heart Association class III or IV) * No myocardial infarction within the past 6 months * No history of congestive heart failure, ventricular arrhythmias, or other arrhythmias requiring therapy Immunologic: * No prior allergy to eggs * No prior autoimmune disease, including the following: * Autoimmune neutropenia, thrombocytopenia, or hemolytic anemia * Systemic lupus erythematosus, Sjogren's syndrome, or scleroderma * Myasthenia gravis * Goodpasture syndrome * Addison's disease, Hashimoto's thyroiditis, or active Graves' disease Other: * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * HIV negative * No other active malignancy except curatively treated carcinoma in situ of the cervix or basal cell skin cancer * No active infection requiring antibiotics * No medical condition that would preclude study PRIOR CONCURRENT THERAPY: Biologic therapy: * At least 4 weeks since prior immunotherapy and recovered Chemotherapy: * See Disease Characteristics * At least 4 weeks since prior chemotherapy and recovered Endocrine therapy: * At least 4 weeks since prior steroids and recovered Radiotherapy: * See Disease Characteristics * At least 4 weeks since prior radiotherapy and recovered Surgery: * Not specified

Sponsors & Collaborators

National Cancer Institute (NCI)
NIHlead

Study Sites (1)

Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support

Bethesda, Maryland, 20892-1182, United States

MeSH Terms

Conditions

Colorectal NeoplasmsEndometrial NeoplasmsHead and Neck NeoplasmsLiver NeoplasmsLung NeoplasmsMelanomaPancreatic NeoplasmsTesticular Germ Cell TumorColonic NeoplasmsCarcinoma, Non-Small-Cell LungSmall Cell Lung CarcinomaCarcinoma, HepatocellularTesticular NeoplasmsThyroid Cancer, PapillaryAdenocarcinoma, FollicularCarcinoma, Medullary

Study Officials

Barry L. Gause, MD
National Cancer Institute (NCI)
STUDY CHAIR

Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Study Completion

Conditions

Keywords

Interventions

Eligibility Criteria

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Study Officials

Study Design

Study Record Dates

Interventions

Condition Hierarchy (Ancestors)

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Study Completion

Conditions

Keywords

Interventions

Eligibility Criteria

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Study Officials

Study Design

Study Record Dates

Interventions

Condition Hierarchy (Ancestors)

Source record

Locations